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AIMS
Proton pump inhibitors (PPIs) belong to the most frequently used drugs, also in patients with cirrhosis. PPIs are extensively
metabolized by the liver, but practice guidance on prescribing in cirrhosis is lacking. We aim to develop practical guidance on the
safe use of PPIs in patients with cirrhosis.
METHODS
A systematic literature search identiﬁed studies on the safety (i.e. adverse events) and pharmacokinetics of PPIs in cirrhotic
patients. This evidence and data from the product information was reviewed by an expert panel who classiﬁed drugs as safe; no
additional risks known; additional risks known; unsafe; or unknown. Guidance was aimed at the oral use of PPIs and categorized by
the severity of cirrhosis, using the Child–Turcotte–Pugh (CTP) classiﬁcation.
RESULTS
A total of 69 studies were included. Esomeprazole, omeprazole and rabeprazole were classiﬁed as having ‘no additional risks
known’. A reduction in maximum dose of omeprazole and rabeprazole is recommended for CTP A and B patients. For patients
with CTP C cirrhosis, the only PPI advised is esomeprazole at a maximum dosage of 20mg per day. Pantoprazole and lansoprazole
were classiﬁed as unsafe because of 4- to 8-fold increased exposure. The use of PPIs in cirrhotic patients has been associated with
the development of infections and hepatic encephalopathy and should be carefully considered.
CONCLUSIONS
We suggest using esomeprazole, omeprazole or rabeprazole in patients with CTP A or B cirrhosis and only esomeprazole in
patients with CTP C. Pharmacokinetic changes are also important to consider when prescribing PPIs to vulnerable, cirrhotic
patients.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Proton pump inhibitors (PPIs) are all metabolized by the liver.
• Pathophysiological changes occurring in cirrhosis affect the pharmacokinetics and pharmacodynamics of drugs.
• The safety of PPIs in cirrhosis has been questioned lately.
WHAT THIS STUDY ADDS
• Exposure to lansoprazole and pantoprazole in patients with cirrhosis was considerably increased while esomeprazole
pharmacokinetics seemed largely spared.
• When used orally, a PPI without large pharmacokinetic changes is recommended in the vulnerable cirrhotic patient.
• Future studies examining the safety of PPIs should also pay attention to differences between PPIs.
Introduction
Proton pump inhibitors (PPIs) are among the most fre-
quently used medications worldwide [1]. They are effective
drugs in suppressing acid secretion and have a wide margin
of safety. In recent years, safety issues have been raised which
led the FDA to issue several warnings [2]. Long-term PPI use
has been associated with increased risk of respiratory infec-
tions, bone fractures and hypomagnesaemia, especially in
older people with comorbidities such as renal or liver disease
[3–5]. In addition, use of PPIs in patients with cirrhosis has
been linked to the development of spontaneous bacterial
peritonitis and hepatic encephalopathy (HE) [6–8]. Intestinal
bacterial overgrowth and translocation are mentioned as pos-
sible causes [9, 10]. These risks are particularly relevant as pa-
tients with cirrhosis frequently use PPIs. Two recent studies
suggest that more than half of cirrhotics received a PPI, often
without a clear indication [6, 11].
All PPIs are metabolized by the liver. The pathophysiolog-
ical changes that accompany cirrhosis affect pharmacokinet-
ics. Portal vein shunting leads to a higher systemic
availability of drugs, while synthetic insufﬁciency results in
low levels of plasma proteins and a higher unbound fraction
[12, 13]. Even so, the activity of drug-metabolizing enzymes
is decreased and biliary excretion can be reduced [12, 13].
These changes often result in higher plasma concentrations
and increased exposure to drugs in patients with cirrhosis.
For PPIs, a rise in exposure can lead to enhanced acid suppres-
sion [14, 15]. This raises questions whether pharmacokinetic
alterations due to cirrhosis inﬂuence the safety proﬁle of PPIs
and whether dose adjustments are needed.
Currently, there is a paucity of practice guidance for the
safe use and dosing of PPIs in cirrhosis. In a previous study,
a method was developed to use pharmacokinetic and safety
data for evaluating drug safety in cirrhosis [16]. In the current
study, we use this method to develop safety and dosing prac-
tical guidance for the use of PPIs in patients with cirrhosis.
Methods
We used a combination of information from registration au-
thorities, literature and expert opinion to develop practical
guidance [16]. A speciﬁc method was needed to translate
the available literature and experience into an easy manage-
able source of information on safe prescribing aimed at the
needs of clinical decision making. A detailed version of this
method has been published before [16]. All PPIs currently
registered in the Netherlands were considered for evalua-
tion. These were: esomeprazole, lansoprazole, omepra-
zole, pantoprazole and rabeprazole. We focused on
developing guidance for the oral use of PPIs; the intravenous
use in gastrointestinal bleeding is considered life-saving and
only used for a short period of time. The safety evaluation
process consisted of several steps. Steps 1–3 were performed
by a pharmacist with experience in evaluating drug safety in
cirrhosis (R.W.). Critical steps were checked by a second
pharmacist/epidemiologist (S.B.).
Step 1: Collection of evidence
Data collection focused on gathering all available evidence
needed to evaluate the safety and pharmacokinetics of PPIs
in cirrhotic patients. This included data from registration au-
thorities (product information) and published literature.
Electronic databases PubMed and Embase were searched and
Web of Science was used for citation tracking. The search
strategy can be found in Table 1. Articles were included if
Table 1
Search strategy used for electronic database search
Pubmed (“Liver cirrhosis”[Mesh] OR cirrho*[ti] OR “hepatic impairment”[ti] OR “liver impairment”[ti] OR “hepatic dysfunction”[ti] OR “liver
dysfunction”[ti] OR “hepatic insufﬁciency”[ti] OR “liver insufﬁciency”[ti]) AND (“Esomeprazole”[Mesh] OR “Omeprazole”[Mesh] OR
“Lansoprazole”[Mesh] OR “Rabeprazole”[Mesh] OR “pantoprazole”[Supplementary Concept] OR “Proton Pump Inhibitors”[Mesh]
OR “Esomeprazole”[tiab] OR “Omeprazole”[tiab] OR “Lansoprazole”[tiab] OR “Rabeprazole”[tiab] OR “pantoprazole”[tiab] OR
“proton pump inhibitor”[tiab] OR “proton pump inhibitors”[tiab])
Embase ‘liver cirrhosis’/exp OR cirrho*:ti OR ‘hepatic impairment’:ti OR ‘liver impairment’:ti OR ‘hepatic dysfunction’:ti OR ‘liver dysfunction’:ti
OR ‘hepatic insufﬁciency’:ti OR ‘liver insufﬁciency’:ti AND (‘omeprazole’/exp OR ‘pantoprazole’/exp OR ‘esomeprazole’/exp OR
‘rabeprazole’/exp OR ‘lansoprazole’/exp OR ‘omeprazole’:ab,ti OR ‘pantoprazole’:ab,ti OR ‘esomeprazole’:ab,ti OR ‘rabeprazole’:ab,ti
OR ‘lansoprazole’:ab,ti) AND [humans]/lim
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(one of) the outcome(s) was safety and/or pharmacokinetics
of a PPI in patients with cirrhosis.
Step 2: Data extraction and presentation
Pharmacokinetic and safety data were extracted from the
American and European authorized product information of
each PPI and presented in a table. If no European product in-
formation was available, the Dutch product information was
used. From the included literature, the study design, number
and characteristics of patients and controls (e.g. severity of
cirrhosis) and details on the intervention were retrieved.
The following data were extracted on the outcome(s):
• Pharmacokinetics: pharmacokinetic parameters of the PPI
[e.g. maximum plasma concentration (Cmax) and area un-
der the curve (AUC)].
• Safety: the number of adverse events (AEs) observed during
PPI use and data on discontinuation due to these events.
Results were reported in summary tables for each outcome
and sorted by level of evidence. The evidence level of each
study was assessed using the treatment harms criteria from
the Oxford Centre for Evidence-Base Medicine [17].
Step 3: Classification and dose suggestion
Based on the collected data, an initial safety classiﬁcation and
dose was suggested for each PPI, if applicable sorted by
severity of cirrhosis. The severity was expressed using the
Child–Turcotte–Pugh (CTP) classiﬁcation [18]. The safety
classiﬁcation could be: safe, no additional risks known, addi-
tional risks known, unsafe, or unknown. Table 2 provides an
overview of the safety classiﬁcation and the actions advised
for health care professionals. Pharmacokinetic data were used
to judge whether a dose adjustment was necessary.
Step 4: Discussion and conclusion by an expert
panel
An expert panel was composed consisting of ten members
with speciﬁc expertise in the treatment of patients with cir-
rhosis, in clinical pharmacology and/or in evidence-based
medicine. These included gastroenterologists, a general prac-
titioner and hospital and community pharmacists. The ex-
pert panel evaluated data extraction and presentation (Steps
1 and 2) and endorsed conclusions derived from the evidence
(Step 3). Likewise, the validity and clinical relevance of the
proposed safety classiﬁcation and suggested dose were
discussed by the expert panel during a meeting. The ﬁnal ad-
vice was based on evidence and clinical experience of the ex-
pert panel and concluded by consensus. All conﬂicts of
interest of the members of the expert panel were identiﬁed,
disclosed and published [16]. The chair of the expert panel
(S.B.) declared no conﬂicts of interest.
Step 5: Implementation
Practical guidance was incorporated in the two national drug
databases in the Netherlands (Pharmabase and G-standard)
and on a free website. Health care professionals will get spe-
ciﬁc alerts when prescribing PPIs in cirrhosis and are referred
to the website for more information.
Step 6: Continuity
To keep the advice up-to-date, literature searches will be
checked yearly and relevant studies will be discussed with
Table 2
Safety classiﬁcation of drugs used in cirrhosis
Description Action
Safe The drug has been evaluated in patients with cirrhosis,
and no increase in harm was found. The safety of the
drug is supported by pharmacokinetic studies and/or
safety studies over a long period. It might be necessary
to use an adjusted dose.
This drug can be used by patients with cirrhosis.
No additional risks known Limited data suggest that this drug does not increase
harm in patients with cirrhosis in comparison with
persons without cirrhosis. It might be necessary to use
an adjusted dose.
The drug can be used in patients with cirrhosis.
Adverse events need to be monitored.
Additional risks known Limited data suggest an increase in patient harm in
patients with cirrhosis compared to persons without
cirrhosis. However, the number of studies is limited
and/or the studies show contradicting results about
the safety in patients with cirrhosis.
This drug should preferably not be used in patients
with cirrhosis if there is a safer alternative available.
Adverse events need to be monitored.
Unsafe Data indicate this drug is not safe in patients with
cirrhosis.
This drug should be avoided in patients with cirrhosis.
Unknown For this drug, insufﬁcient data are available to
evaluate the safety in patients with cirrhosis.
This drug should preferably not be used in patients
with cirrhosis if there is a safer alternative available.
Individual judgement of therapeutic need vs. additional
risks in patients with cirrhosis. Adverse events need
to be monitored.
Adapted from: Weersink et al. [16]
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the expert panel. Once every ﬁve years, a complete update is
planned.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY [19], and are
permanently archived in the Concise Guide to PHARMA-
COLOGY 2017/18 [20].
Results
The developed practical guidance is based on information
from the product information (Table 3) [21–30] and data ex-
tracted from 69 articles included in the literature review
(Figure 1) [6–8, 11, 31–95]. Twelve of the included studies fo-
cused on pharmacokinetics (Table 4), 51 on safety, and six
studied both safety and pharmacokinetics of PPIs. Of the
safety studies, 20 speciﬁcally investigated the safety of an in-
dividual PPI (Table 5), while 37 studied safety issues of PPIs as
a group (Table S1).
Esomeprazole
In a multiple-dose pharmacokinetic study (level 4) exposure
to esomeprazole in eight cirrhotic patients with CTP A and B
was comparable with healthy controls, while it more than
doubled in four CTP C patients (Table 4) [31]. This study was
also mentioned in the product information, where a maxi-
mum dosage of 20 mg is advised in CTP C patients (Table 3)
[21, 22]. Regarding safety, in one case report esomeprazole
was tolerated well (Table 5) [53]. In the pharmacokinetic
study, 25% of 12 patients suffered an adverse event (i.e. con-
stipation, diarrhoea and HE) when using 40 mg per day for
ﬁve days. The patient with HE had severe cirrhosis.
Expert judgement. Based on these limited data, esomeprazole
was classiﬁed as ‘no additional risks known’. In CTP C
patients, the evidence is very thin (one study in four
subjects). Because of a doubling in exposure in CTP C
patients, the recommendations of the product information
are adopted to use no more than 20 mg per day in CTP C
patients.
Omeprazole
In ten studies (level 3 and 4) with a total of 140 patients, the
pharmacokinetics of omeprazole were explored (Table 4)
[33–37, 47, 57–60]. Two articles showed higher exposure with
increasing severity of cirrhosis, and a modelling study pre-
dicted the same [33, 34, 36]. In CTP A, the AUC was slightly
higher in comparison with healthy controls, in CTP B it was
doubled, and exposure was more than doubled in CTP C pa-
tients. Two other single-dose studies found a higher increase
in exposure (seven- to eightfold), but the severity of cirrhosis
was not described [35, 37]. In healthy persons, omeprazole
has an elimination half-life of less than 1 h, prolonging in pa-
tients with cirrhosis to 2–4 h [47, 57, 60]. Elimination half-life
seems to increase with severity of cirrhosis [34].
The safety of omeprazole has been described in ten arti-
cles (level 2, 3 and 4) with 220 cirrhotic subjects (Table 5)
[34, 36, 41, 44, 46–49, 51, 55]. In eight of these studies only
mild AEs occurred with omeprazole treatment, even when
treatment lasted for more than four weeks. More severe ad-
verse events (epigastric pain, arthralgia and worsening of
HE) were seen in a study where patients received a continu-
ous infusion for two days [36]. Furthermore, in a case report,
a patient with decompensated cirrhosis developed neurolog-
ical adverse events (tremor, disbalance and confusion) while
being on omeprazole treatment [55].
Expert judgement. In the clinical studies where patients were
sorted by CTP class, exposure increased with severity of
cirrhosis to an almost threefold higher exposure in CTP C
compared to healthy controls. Two studies measured a
seven- and eightfold increase in exposure in cirrhotics with
unknown severity. In the literature about safety, omeprazole
was mostly well tolerated. However, neurological AEs were
reported in patients who received a high intravenous dose
and in a patient with severe cirrhosis. In CTP A and B
patients, omeprazole is classiﬁed as ‘no additional risks
known’ if a maximum dose of 20 mg per day is used. In CTP
C, omeprazole is classiﬁed as ‘unsafe’ based on the
signiﬁcant pharmacokinetic alterations and it is advised to
avoid its usage.
Lansoprazole
Pharmacokinetics of lansoprazole were explored in four arti-
cles (level 3 and 4) with a total of 38 cirrhotic patients [32,
33, 60, 61]. In a single-dose study, the AUC was more than
fourfold higher in compensated and in decompensated cir-
rhotics compared to healthy controls (Table 4) [32]. A model-
ling study also predicted increased exposure, especially in
CTP C patients [33]. The FDA label [24] described an incre-
ment in the AUC of up to 500% in patients with various de-
grees of hepatic impairment, while the Dutch product
information [23] mentioned a doubling in AUC in mild he-
patic impairment and a higher increase in moderate to severe
hepatic impairment (Table 3). The FDA label and three stud-
ies describe a prolongation of the half-life from 1.5 h in
healthy subjects to 6–7 h in cirrhotics [24, 32, 60, 61].
In three case reports and one other study (level 3 and 4)
the safety of lansoprazole was explored in a total of 33 cir-
rhotic patients (Table 5) [50, 53–55]. In the case reports severe
AEs happened that were probably caused by lansoprazole (i.e.
DRESS syndrome, anaphylactic reaction and neurological ad-
verse events) [53–55]. In the fourth study, only mild AEs oc-
curred during two weeks of treatment [50].
Expert judgement. For all CTP classes lansoprazole is
classiﬁed as ‘unsafe’, based on the marked increase in
exposure compared to healthy controls and the availability
of PPIs without these pharmacokinetic changes. It is
recommended to avoid the use of lansoprazole in patients
with cirrhosis.
Pantoprazole
We identiﬁed six pharmacokinetic studies (level 3 and
4) with pantoprazole in 77 cirrhotic patients (Table 4)
[33, 38, 39, 56, 60, 62]. In two multiple-dose studies,
the AUC was ﬁve- to sevenfold higher in patients with
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Table 3
Special warnings of the European and US product information regarding the use of PPIs in patients with cirrhosis
PPI SmPCa FDA label
Esomeprazole
[21, 22]
In patients with mild or moderate hepatic impairment,
the metabolism of esomeprazole could be decreased.
In patients with severe hepatic impairment, the
metabolism of esomeprazole is decreased leading to
a doubling of the AUC. Therefore, do not exceed the
maximum dose of 20 mg in patients with severe hepatic
impairment. Esomeprazole and main metabolites do
not tend to accumulate with once daily dosing.
The steady state pharmacokinetics of esomeprazole obtained after
administration of 40 mg once daily to four patients each with mild
(Child–Pugh A), moderate (Child–Pugh Class B), and severe (Child–
Pugh Class C) liver insufﬁciency were compared to those obtained
in 36 male and female Gastro-oesophageal Reﬂux Disease patients
with normal liver function. In patients with mild and moderate
hepatic insufﬁciency, the AUCs were within the range that could
be expected in patients with normal liver function. In patients with
severe hepatic insufﬁciency, the AUCs were 2–3 times higher than in
the patients with normal liver function. No dosage adjustment is
recommended for patients with mild to moderate hepatic
insufﬁciency (Child–Pugh Classes A and B). However, in patients
with severe hepatic insufﬁciency (Child–Pugh Class C), a dose of
20 mg once daily should not be exceeded.
Lansoprazole
[23, 24]
The exposure to lansoprazole is doubled in patients
with mild hepatic impairment and much more
increased in patients with moderate to severe hepatic
impairment. Patients with moderate to severe hepatic
impairment should be kept under regular supervision
and a 50% reduction of the daily dose is
recommended.
In patients with various degrees of chronic hepatic impairment,
the mean plasma half-life of lansoprazole was prolonged from
1.5 h to 3.2–7.2 h. An increase in the mean AUC of up to 500%
was observed at steady state in hepatically-impaired patients
compared to healthy subjects. Consider dose reduction in
patients with severe hepatic impairment.
Omeprazole
[25, 26]
In patients with hepatic impairment, the metabolism
of omeprazole is decreased causing a higher AUC.
The once daily dosing of omeprazole has no tendency
to accumulate. For patients with hepatic impairment,
a daily dose of 10–20 mg may be sufﬁcient.
In patients with chronic hepatic disease, the bioavailability
increased to approximately 100% compared with an IV dose,
reﬂecting decreased ﬁrst-pass effect, and the plasma half-life of
the drug increased to nearly 3 h compared with the half-life in
normal subjects of 0.5–1 h. Plasma clearance averaged
70 ml min1, compared with a value of 500–600 ml min1 in
normal subjects. Dose reduction, particularly where maintenance
of healing of erosive esophagitis is indicated, for the hepatically
impaired should be considered.
Pantoprazole
[27, 28]
Although for patients with liver cirrhosis (Child–Pugh
A and B) the half-life increased to 7–9 h, and the AUC
increased by a factor 5–7, the maximum serum
concentration only increased by a factor of 1.5
compared to healthy individuals. In patients with
severe hepatic impairment, a daily dose of 20 mg
of pantoprazole may not be exceeded. Pantoprazole
40 mg should not be used in combination therapy for
the eradication of H. pylori in patients with moderate
to severe hepatic impairment, since no data are
available on the efﬁcacy and safety. Liver enzymes
in patients with severe hepatic impairment should
be monitored regularly. If there is an increase in
liver enzyme values, the treatment should be stopped
In patients with mild to severe hepatic impairment (Child–Pugh
A–C cirrhosis), maximum pantoprazole concentrations increased
only slightly (1.5-fold) relative to healthy subjects. Although serum
half-life values increased to 7–9 h and AUC values increased by ﬁve-
to sevenfold in hepatic-impaired patients, these increases were
no greater than those observed in CYP2C19 poor metabolizers,
where no dosage adjustment is warranted. These pharmacokinetic
changes in hepatic-impaired patients result in minimal drug
accumulation following once-daily, multiple-dose administration.
No dosage adjustment is needed in patients with mild to severe
hepatic impairment. Doses higher than 40 mg day1 have not
been studied in hepatically impaired patients.
Rabeprazole
[29, 30]
In patients with mild to moderate hepatic impairment,
the AUC doubled compared to healthy volunteers after
administration of a single dose of 20 mg rabeprazole,
and there was a two- to three-fold increase in the
half-life of rabeprazole. After a daily dose of 20 mg for
7 days, however, the AUC was increased only by a factor
of 1.5 and the Cmax only by a factor of 1.2. In patients
with hepatic impairment, the half-life of rabeprazole
was 12.3 h compared to 2.1 h in healthy volunteers.
The pharmacodynamic response in the two groups
(determination of pH in the stomach) was clinically
comparable. For patients with hepatic impairment,
no dose adjustments are required.
In a single-dose study of 10 patients with chronic mild to moderate
compensated cirrhosis of the liver who were administered a 20 mg
dose of rabeprazole, AUC was approximately doubled, the elimination
half-life was two- to threefold higher, and total body clearance was
decreased to less than half compared to values in healthy men. In a
multiple-dose study of 12 patients with mild to moderate hepatic
impairment administered 20 mg rabeprazole once daily for eight
days, AUC and Cmax values increased approximately 20% compared
to values in healthy age- and gender-matched subjects. These increases
were not statistically signiﬁcant. No information exists on rabeprazole
disposition in patients with severe hepatic impairment. Administration
of rabeprazole to patients with mild to moderate liver impairment
resulted in increased exposure and decreased elimination. Due to the
lack of clinical data on rabeprazole in patients with severe hepatic
impairment, caution should be exercised in those patients.
AUC, area under the curve; Cmax, maximum plasma concentration; PPI, proton pump inhibitor; SmPC, summary of product characteristics.
aTranslated from Dutch.
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cirrhosis compared to healthy controls after oral and intrave-
nous dosing. The same increase is described in the product in-
formation of pantoprazole (Table 3) [27, 28]. Another article
found a similar exposure to pantoprazole for patients with
CTP B and CTP C cirrhosis and controls who were slow
CYP2C19 metabolizers [56]. When comparing these data
with healthy controls, the AUC was ﬁve times higher in the
cirrhotic patients. A modelling study predicted the same in-
creases in exposure [33]. In healthy persons, pantoprazole
has an elimination half-life of approximately 1 h. Five studies
found an elimination half-life of 7–9 h in patients with cir-
rhosis [38, 39, 56, 60, 62].
Three articles (level 2, 3 and 4) studied the safety of
pantoprazole in 101 patients with cirrhosis (Table 5) [41,
43, 56]. Pantoprazole was mostly well tolerated. In one
study, a CTP C patient developed HE and in a randomized
trial two patients suffered from fever possibly related to
PPI use [41, 56].
Expert judgement. For all CTP classes, pantoprazole is
classiﬁed as ‘unsafe’, based on the marked increase in
exposure and prolonged half-life, which cannot be corrected
by dose reduction. Since there are alternatives without these
large increases in exposure, we would recommend avoiding
the use of pantoprazole in cirrhotic patients.
Rabeprazole
Two pharmacokinetic studies (level 3 and 4) were retrieved
including 10 cirrhotic patients (Table 4) [33, 40]. Exposure
to rabeprazole more than doubled in patients with compen-
sated cirrhosis compared to healthy controls [40]. In a model-
ling study this was also predicted for CTP A cirrhosis, while
exposure increased more than threefold in CTP B and ﬁvefold
in CTP C cirrhosis [33]. In an article described in the product
information (Table 3), there was no accumulation of
rabeprazole after multiple doses in patients with CTP A and
B [29, 30]. The intragastric pH was comparable between cir-
rhotics and healthy controls. Rabeprazole has an elimination
half-life of 1 h, prolonging to almost 4 h in cirrhotics after a
single dose and to 12 h after multiple dosing [40].
Three articles (level 2 and 3) studied the safety of
rabeprazole in 101 cirrhotics (Table 5) [40, 42, 45]. In two,
rabeprazole was well tolerated with only mild adverse events
[40, 42]. In a post-marketing surveillance study, nine of 70 pa-
tients with cirrhosis (13%) suffered an AE [45]. These were se-
vere in two (one HE and one serious elevation in bilirubin),
both recovered after discontinuation.
Expert judgement. For CTP A and B patients, rabeprazole is
classiﬁed as ‘no additional risks known’ and a starting dose
of 10 mg is recommended, based on the doubled exposure.
In CTP B patients, maintaining the 10 mg dose level is
advised. As there are no clinical data from CTP C patients
and a modelling study predicted an increase in AUC of more
than ﬁvefold, it is, again, advised to use a PPI without these
large changes and rabeprazole is classiﬁed as ‘unsafe’ in CTP
C patients.
Safety of PPIs as group
Thirty-seven articles studied the safety of PPIs as a group in
patients with cirrhosis (Table S1) [6–8, 11, 63–95]. These stud-
ies mostly focused on the risk of spontaneous bacterial perito-
nitis or infections in general. A few recent ones also examined
the risk of HE.
Risk of spontaneous bacterial peritonitis
Twenty-four observational studies (level 3 and 4) [6, 69–73,
75, 76, 78, 79, 81–90, 92–95] and seven systematic reviews
(level 2) [7, 63–68] explored the risk of spontaneous bacterial
peritonitis with PPI use in cirrhotics. All meta-analyses de-
tected a signiﬁcant association between PPI use and the de-
velopment of spontaneous bacterial peritonitis [7, 63–67].
These meta-analyses included at least four studies [67] and
at most 17 [65]. Heterogeneity was high in some meta-
analyses, the meta-analysis of Trikudanathan et al. [67] had
the lowest heterogeneity (22%) and found an odds ratio of
2.77 [95% conﬁdence interval (CI) 1.82–4.23]. In the
meta-analysis of Yu and colleagues, a sub-analysis of only
the cohort studies retrieved an odds ratio of 1.18 (95% CI
0.99–1.41) without heterogeneity (0%) [64].
No meta-analysis incorporated dose or duration of PPI
therapy in their risk calculation. Of the observational studies,
four speciﬁcally investigated the duration of therapy. In
three, a longer duration of PPI use was linked to a higher risk
of spontaneous bacterial peritonitis [71, 82, 90], while in the
other, no such relation was found [72]. Four additional stud-
ies speciﬁed the dose used by cirrhotics [78, 84, 92, 93]. One
found a higher risk with twice daily dosing versus once daily
dosing [93], while two others did not [84, 92]. The fourth
Figure 1
Flowchart of study selection process
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Table 4
Summary table of pharmacokinetic studies of PPIs in patients with cirrhosis, sorted by Child–Pugh class [18]
Ref. Evidence level Intervention
Results (expressed as ratioa)
Parameter Controls
Cirrhotic patients
CTP A CTP B CTP C
[31] 4 Esomeprazole (40 mg day1
for 5 days)
n = 36
(literature)
n = 4 n = 4 n = 4
Cmax 1 1.38 1.15 1.36
AUCt 1 1.42 1.77 2.34
[32] 3 Lansoprazole (single dose
of 30 mg)
n = 18 n = 8
(compensated)
n = 8
(decompensated)
Cmax 1 1.39 1.10
AUC0–48 h 1 4.38 4.01
[33] 4 Lansoprazole (PK modelling) AUCtotal 1 2.94 4.13 7.56
AUCunbound 1 3.19 5.41 12.73
[34] 3 Omeprazole (single dose
of 20 mg)
n = 10 n = 10 n = 10 n = 10
Cmax 1 0.95 1.15 1.32
AUC∞ 1 1.69 2.71 2.79
[35] 3 Omeprazole (single dose
of 20 mg)
n = 8 n = 8 (CTP unknown)
Cmax 1 2.55
AUC∞ 1 8.38
[36] 4 Omeprazole (80 mg
bolus + 8 mg h1
continuous infusion
for 47.5 h; total 460 mg)
n = 12 n = 5 n = 4 n = 3
Cmax 1 1.49
AUC0–48 h 1 1.59 1.85 2.14
[37] 4 Omeprazole (single
dose of 40 mg)
n = 18
(literature)
n = 3 n = 4 n = 1
Cmax 1 2.57
AUC∞ 1 7.3
[33] 4 Omeprazole (PK modelling) AUCtotal 1 2.65 3.61 6.96
AUCunbound 1 3.23 5.04 10.74
[38] 3 Pantoprazole (40 mg day1
for 7 days)
n = 12 n = 12 (CTP A+B)
Cmax 1 1.55
AUC0–24 h 1 6.77 (5.3–7.8)
Pantoprazole (30 mg day1
IV for 5 days)
n = 8 n = 12 (CTP A+B)
Cmax 1 1.66
AUC0–24 h 1 5.03
[39] 3 Pantoprazole (40 mg day
1
for 7 days)
n = 12 (CTP unknown)
Cmax 1 1.44
AUC0–24 h 1 6.6
Pantoprazole (30 mg day1
IV for 5 days)
Cmax 1 1.62
AUC0–24 h 1 5.5
[33] 4 Pantoprazole (PK modelling) AUCtotal 1 2.49 2.90 3.80
AUCunbound 1 2.70 3.79 6.35
[40] 3 Rabeprazole (single dose
of 20 mg)
n = 13 n = 10 (compensated)
Cmax 1 1.58
AUC0–24 h 1 2.20
[33] 4 Rabeprazole (PK modelling) AUCtotal 1 1.98 2.34 3.09
AUCunbound 1 2.42 3.29 5.15
Presented are studies that determined the AUC for patients with cirrhosis and compared it to healthy controls. Studies determining other pharma-
cokinetic parameters are presented in the text. AUC, area under the curve; Cmax, peak plasma concentration; CTP, Child–Turcotte–Pugh class; IV,
intravenous; PK, pharmacokinetic; Ref, reference.
aRatio: value for Cmax or AUC divided by the value of the control group.
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study compared the risk between a half PPI dose and a full
dose and did not ﬁnd a difference [78].
Risk of infections
In 11 observational studies (level 3 and 4) and two systematic
reviews (level 2) the risk of bacterial infection with PPI use in
cirrhotics was determined [11, 65, 68, 72–75, 77, 79–81, 87,
91]. In the meta-analysis of Xu et al. [65], the odds ratio for
bacterial infection was 1.98 (95%CI 1.36–2.87, heterogeneity
0%). Two studies also calculated the dose-dependent risk of
infections [81, 87]. One of these did not ﬁnd differences in
dose between patients who developed an infection and pa-
tients who did not [81]. The other notedmore AEs with an in-
adequate dosed PPI (too high or contra-indicated) [87].
Risk of HE
Six observational studies (level 3, 4) looked at the risk of HE
with the use of PPIs [6, 8, 69–72]. Four found an increased risk
of HE with PPI use in cirrhotics [6, 8, 69, 70], while two did
not [71, 72]. The case–control study of Tsai and colleagues
[8] provided sub-analyses per PPI and per dose and duration
of treatment. They found a positive relationship between
HE risk and cumulative deﬁned daily doses. The highest risk
was found for pantoprazole, followed by lansoprazole, omep-
razole and esomeprazole. The risk of HE with rabeprazole was
not statistically signiﬁcant but had the largest conﬁdence in-
terval due to a low number of users.
Expert judgement. There is conﬂicting data for all outcomes
of interest. Only one study provided sub-analyses for the
risk of HE per PPI. Based on these results, it is possible that
pharmacokinetic alterations contributed to an increased
risk. We advise to cautiously use PPIs in cirrhotics and
monitor for these AEs during treatment.
Implementation and continuity
The practical guidance on PPIs has been implemented in the
two national drug databases in the Netherlands in 2017.
The ﬁrst update is planned for 2022.
Discussion
We developed practical guidance for the safe use of PPIs in
patients with cirrhosis based on the product information,
literature and expert opinion. Our results show that relevant
changes in pharmacokinetics occur due to cirrhosis. Based
on the available evidence, we recommend esomeprazole,
omeprazole and rabeprazole for use in patients with CTP A
and B cirrhosis. In CTP C cirrhosis, we recommend to
prescribe only esomeprazole whereas the use of lansoprazole
and pantoprazole in all patients with cirrhosis is
discouraged because of increased exposure compared to
non-cirrhotics.
Our advice is based on evidence from both the pharmaco-
kinetic and safety literatures. We found no studies that com-
bined pharmacokinetic data with pharmacodynamic data.
Literature shows that the AUC is the best pharmacokinetic
parameter predicting gastric acid suppression [14, 15]. The
main question is whether increased acid suppression is aTa
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safety risk for patients with cirrhosis, an issue that is virtually
not covered in the product information. In the included stud-
ies, most AEs were mild, but there were cases of HE that were
attributed to PPI use. However, the causality is unclear since
HE is a central feature of advanced cirrhosis. Almost all of
these events occurred in patients on a relatively high dose
or in patients with advanced cirrhosis. Some articles exam-
ining the safety of PPIs as a group also assessed dose-
dependent safety [8, 78, 81, 84, 87, 92, 93]. Results were
conﬂicting. One study performed a sub-analysis for
assessing the risk of HE per PPI [8]. They found the highest
risk of HE with pantoprazole and no signiﬁcant risk with
rabeprazole. The risk of HE for the remaining PPIs was com-
parable. An important consideration for the expert panel
was not to expose cirrhotic patients to unnecessary risks.
Highly increased exposure was considered a safety risk when
used in non-acute settings; hence for daily practice we dis-
courage the oral use of lansoprazole and pantoprazole in cir-
rhosis and recommend the use of PPIs without these large
increases, such as esomeprazole.
Our results demonstrate major pharmacokinetic alter-
ations in patients with cirrhosis compared to healthy con-
trols. Although maximum plasma concentrations were
often comparable between cirrhotics and healthy controls,
the exposure (AUC) and elimination half-life differed to a
great extent between the two groups. All PPIs are metabolized
by CYP2C19 and to a lesser extent by CYP3A4. CYP2C19 is
very sensitive to impairment of liver function [96]. Reduced
activity of CYP2C19 is probably the most important cause
of the observed pharmacokinetic changes. There were also
signiﬁcant differences found between PPIs. The changes in
pharmacokinetics were largest for lansoprazole and
pantoprazole. Both have a low hepatic extraction ratio, while
the other PPIs have an intermediate hepatic extraction ratio
[13, 31]. In contrast to drugs with an intermediate hepatic ex-
traction ratio, hepatic clearance of drugs with a low hepatic
extraction ratio is mostly dependent on intrinsic metabolic
clearance (i.e. activity of metabolizing enzymes) and on pro-
tein binding. Drugs with a low hepatic extraction ratio are
therefore most vulnerable to changes in the activity of he-
patic metabolizing enzymes and in protein binding [13].
Esomeprazole pharmacokinetics seemed to be least inﬂu-
enced by cirrhosis. It is remarkable that results of
esomeprazole and omeprazole differ. This can be explained
by differences in metabolism between the S-enantiomer and
the R-enantiomer of omeprazole, as the S-enantiomer
(esomeprazole) is metabolized to a lesser extent by CYP2C19
than the R-enantiomer [97]. Pharmacogenetic studies with
PPIs in healthy volunteers also showed that exposure of
esomeprazole is least affected by CYP2C19 polymorphisms
compared to other PPIs [98, 99].
The literature search identiﬁed many studies that deter-
mine the risk of HE, spontaneous bacterial peritonitis
and/or infections in patients with cirrhosis using PPIs. Most
of these were observational and cross-sectional by design
and provide conﬂicting results. The nature and quality of
the data do not allow a formal meta-analysis, which pre-
cluded a direct comparison. Cautious use of PPIs in these
patients is recommended by most authors. Of note is that
only one of the 37 studies examined safety risks for each
individual PPI, while eight did investigate whether safety
risks were dose-dependent. In our opinion, a sub-analysis
on the dose-dependency of the risk of HE or infections can-
not be calculated in the absence of pharmacokinetic data.
For further studies, determining the risk of spontaneous
bacterial peritonitis, HE or infections for each PPI would
be advisable.
A strength of our study is that we are not only reviewing
the literature, but also developing practical guidance for
health care professionals by combining literature and regis-
tration information with expert opinion. For some outcomes
(e.g. pharmacokinetics in CTP C patients), our recommenda-
tions are limited by the few studies available. Therefore, con-
tinuous update of data and advice is warranted. Another
strength is that the method used for combining all these data
has been peer-reviewed and published [16]. A limitation of
this method is that a number of steps were performed by a
single author (R.W.). The most critical steps (i.e. data synthe-
sis, advice formulation) were however, double checked by a
second person (S.B.). Interpretation of the ﬁndings, discus-
sion and conclusion was in all cases done by a multi-
disciplinary expert panel.
We provided safety and dosing guidance for the oral use
of PPIs in patients with cirrhosis which can be applied in
daily practice. The pharmacokinetic properties of PPIs are af-
fected by the presence of cirrhosis. The combination of phar-
macokinetic and safety data used in this study is unique and
sheds new light on the current discussion about the safety
of PPIs in patients with cirrhosis.
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